


477 Rec'd PCT/PTO 11 OCT 2000

FORM PTO-1390 (Modified) (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER <b>NIDN-10369</b>
<b>TRANSMITTAL LETTER TO THE UNITED STATES</b> <b>DESIGNATED/ELECTED OFFICE (DO/EO/US)</b> <b>CONCERNING A FILING UNDER 35 U.S.C. 371</b>			U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR) <b>To be assigned 09/673160</b>

INTERNATIONAL APPLICATION NO. <b>PCT/GB99/01234</b>	INTERNATIONAL FILING DATE <b>April 22, 1999</b>	PRIORITY DATE CLAIMED <b>April 22, 1998</b>
--	--	--

TITLE OF INVENTION <b>Ultrasound Contrast Agent</b>
--

APPLICANT(S) FOR DO/EO/US <b>Balinov, et al.</b>
---



Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

**Items 13 to 20 below concern document(s) or information included:**

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

**Return Postcard**

Copy of the International Application as Published by the International Bureau

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR 1.53) <b>09/673160</b> Date assigned	INTERNATIONAL APPLICATION NO. <b>PCT/GB99/01234</b>	ATTORNEY'S DOCKET NUMBER <b>NIDN-10369</b>
--	--	---


21. The following fees are submitted: <b>BASIC NATIONAL FEE ( 37 CFR 1.492 (a) (1) - (5) ) :</b> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... <b>\$970.00</b> <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$840.00</b> <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$690.00</b> <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$670.00</b> <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$96.00</b> <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				<b>CALCULATIONS PTO USE ONLY</b>	
				<b>\$840.00</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				<b>\$0.00</b>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	22 - 20 =	2	x \$18.00	<b>\$36.00</b>	
Independent claims	2 - 3 =	0	x \$78.00	<b>\$0.00</b>	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$876.00</b>	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	
<b>SUBTOTAL =</b>				<b>\$876.00</b>	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				<b>\$0.00</b>	
<b>TOTAL NATIONAL FEE =</b>				<b>\$876.00</b>	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				<b>\$0.00</b>	
<b>TOTAL FEES ENCLOSED =</b>				<b>\$876.00</b>	
				Amount to be:	\$
				refunded	
				charged	\$

☐ A check in the amount of \_\_\_\_\_ to cover the above fees is enclosed.

☒ Please charge my Deposit Account No. **500-588** in the amount of **\$876.00** to cover the above fees.  
 A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **500-588** A duplicate copy of this sheet is enclosed.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO:  <b>Royal N. Ronning, Jr.</b> <b>Amersham Pharmacia Biotech, Inc.</b> <b>800 Centennial Avenue</b> <b>Piscataway, New Jersey 08855</b>  <b>(732) 457-8423</b>	<div style="text-align: center;">                           SIGNATURE                     </div> <div style="text-align: center;"> <b>Royal N. Ronning, Jr.</b>                          NAME                     </div> <div style="text-align: center;"> <b>32,529</b>                          REGISTRATION NUMBER                     </div> <div style="text-align: center;"> <b>October 11, 2000</b>                          DATE                     </div>
--	---

09/673160

529 Rec'd PCT/PTO 11 OCT 2000

NIDN-10369

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: B. Balinov, et al.

Group Art Unit: To be assigned

Serial number: To be assigned

Examiner: To be assigned

Filing Date: October 11, 2000

Title: Ultrasound Contrast Agent

**FIRST PRELIMINARY AMENDMENT**

Honorable Assistant Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

Applicants respectfully request the entry of the following preliminary amendment in connection with the prosecution of the captioned application, which claims priority to PCT Patent Application PCT/GB99/01234.

**IN THE CLAIMS**

In Claim 5, lines 1-2, please delete "any of the preceding claims" without prejudice and substitute--Claim 1--therefor.

In Claim 8, lines 1-2, please delete "any of the preceding claims" without prejudice and substitute--Claim 1--therefor.

In Claim 10, lines 1-2, please delete "any of the preceding claims" without prejudice and substitute--Claim 1--therefor.

In Claim 11, line 1, please delete "any of claims 1-9" without prejudice and substitute--Claim 1--therefor.

In Claim 12, lines 1-2, please delete "any of the preceding claims" without prejudice and substitute--Claim 1--therefor.

In Claim 15, line 2, please delete "any of claims 1-12" without prejudice and substitute--Claim 1--therefor.


In Claim 18, lines 3-4, please delete "any of claims 1-14" without prejudice and substitute--Claim 1--therefor.

In Claim 21, lines 1-2, please delete "any of claims 1-12" without prejudice and substitute--Claim 1--therefor.

09/673160 "PAT" 09/12/99

Applicants have amended Claims 5, 8, 10, 11, 12, 15, 18, and 21 to delete multiple dependencies. Applicants respectfully submit that the claims, as amended, are fairly based on the specification, and respectfully request their entry.

Respectfully submitted,

  
Royal N. Ronning, Jr. 32,529  
Attorney for Applicants

Amersham Pharmacia Biotech Inc.  
800 Centennial Avenue  
P. O. Box 1327  
Piscataway, NJ 08855-1327  
Tel: (732) 457-8423

Improvements in or relating to contrast agents

5           This invention relates to ultrasound imaging, more particularly to novel contrast agent preparations and their use in ultrasound imaging, for example in visualising tissue perfusion.

10           It is well known that contrast agents comprising dispersions of microbubbles of gases are particularly efficient backscatterers of ultrasound by virtue of the low density and ease of compressibility of the microbubbles. Such microbubble dispersions, if  
15           appropriately stabilised, may permit highly effective ultrasound visualisation of, for example, the vascular system and tissue microvasculature, often at advantageously low doses.

20           The use of ultrasonography to assess blood perfusion (i.e. blood flow per unit of tissue mass) is of potential value in, for example, tumour detection, tumour tissue typically having different vascularity from healthy tissue, and studies of the myocardium, e.g. to detect myocardial infarctions. A problem with the application of existing ultrasound contrast agents to  
25           cardiac perfusion studies is that the information content of images obtained is degraded by attenuation caused by contrast agent present in the ventricles of the heart.

30           In our copending International Patent Publication No. WO-A-9817324, the contents of which are incorporated herein by reference, we have disclosed that ultrasonic visualisation of a subject, in particular of perfusion in the myocardium and other tissues, may be achieved and/or enhanced by means of gas-containing contrast  
35           agent preparations which promote controllable and temporary growth of the gas phase *in vivo* following administration. Such contrast agent preparations may be

09/673160 121100

used to promote controllable and temporary retention of the gas phase, for example in the form of microbubbles, in tissue microvasculature, thereby enhancing the concentration of gas in such tissue and accordingly enhancing its echogenicity, e.g. relative to the blood pool.

Such use of gas as a deposited perfusion tracer differs markedly from existing proposals regarding intravenously administrable microbubble ultrasound contrast agents. Thus it is generally thought necessary to avoid microbubble growth since, if uncontrolled, this may lead to potentially hazardous tissue embolisation. Accordingly it may be necessary to limit the dose administered and/or to use gas mixtures with compositions selected so as to minimise bubble growth in vivo by inhibiting inward diffusion of blood gases into the microbubbles (see e.g. WO-A-9503835 and WO-A-9516467).

In accordance with WO-A-9817324, on the other hand, a composition comprising a dispersed gas phase is coadministered with a composition comprising at least one substance which has or is capable of generating a gas or vapour pressure in vivo sufficient to promote controllable growth of the said dispersed gas phase through inward diffusion thereto of molecules of gas or vapour derived from said substance, which for brevity is hereinafter referred to as a "diffusible component", although it will be appreciated that transport mechanisms other than diffusion may additionally or alternatively be involved in operation of the invention, as discussed in greater detail hereinafter.

This coadministration of a dispersed gas phase-containing composition and a composition comprising a diffusible component having an appropriate degree of volatility may be contrasted with previous proposals regarding administration of volatile substances alone, e.g. in the form of phase shift colloids as described in

09673460 121100

WO-A-9416739. Thus the contrast agent preparations of  
WO-A-9817324 permit control of factors such as the  
probability and/or rate of growth of the dispersed gas  
by selection of appropriate constituents of the  
5 coadministered compositions, whereas administration of  
the aforementioned phase shift colloids alone may lead  
to generation of microbubbles which grow uncontrollably  
and unevenly, possibly to the extent where at least a  
proportion of the microbubbles may cause potentially  
10 dangerous embolisation of, for example, the myocardial  
vasculature and brain (see e.g. Schwarz, *Advances in  
Echo-Contrast [1994(3)]*, pp. 48-49).

It has been found that administration of phase  
shift colloids alone may not lead to reliable or  
15 consistent *in vivo* volatilisation of the dispersed phase  
to generate gas or vapour microbubbles. Grayburn et al.  
in *J. Am. Coll. Cardiol.* 26(5) [1995], pp. 1340-1347  
suggest that preactivation of perfluoropentane emulsions  
may be required to achieve myocardial opacification in  
20 dogs at effective imaging doses low enough to avoid  
haemodynamic side effects. An activation technique for  
such colloidal dispersions, involving application of  
hypobaric forces thereto, is described in WO-A-9640282;  
typically this involves partially filling a syringe with  
25 the emulsion and subsequently forcibly withdrawing and  
then releasing the plunger of the syringe to generate a  
transient pressure change which causes formation of gas  
microbubbles within the emulsion. This is an inherently  
somewhat cumbersome technique which may fail to give  
30 consistent levels of activation.

Again with regard to phase shift colloids, it is  
stated in US-A-5536489 that emulsions of water-insoluble  
gas-forming chemicals such as perfluoropentane may be  
used as contrast agents for site-specific imaging, the  
35 emulsions only generating a significant number of image-  
enhancing gas microbubbles upon application of  
ultrasonic energy to a specific location in the body

09673150 121100

which it is desired to image. Our own research has shown, however, that emulsions of volatile compounds such as 2-methylbutane or perfluoropentane give no detectable echo enhancement either *in vitro* or *in vivo* when ultrasonicated at energy levels which are sufficient to give pronounced contrast effects using two component contrast agents in accordance with WO-A-9817324.

WO-A-9725097 discloses the administration of aqueous dispersions of superheated droplets of water-immiscible liquids which may be vaporised *in vivo* under the influence of radiation or ultrasound, which are said to induce homogeneous nucleation of the droplets. The dispersions may be used, *inter alia*, to form diagnostic contrast agents or selectively to deliver drugs to a localised body region.

The present invention is based on the finding that volatile emulsions of the phase shift colloid type in which gas-containing heterogeneous nucleation sites are associated with the emulsion droplets possess a number of valuable advantages. In particular, they permit perfusion imaging to be carried out in similar manner to that described in WO-A-9817324, but without the need to administer two separate compositions, thereby facilitating handling of the products. Moreover, factors such as the ultimate size of the gas microbubbles generated by the volatile dispersed phase may be controlled through parameters such as the droplet size of the emulsion and the nature and location of the nucleation sites which may readily be set during manufacture of the contrast agent. Thus the high yield of liquid-to-gas phase transition resulting from the presence of nucleation sites make it possible accurately to forecast the size of the formed microbubbles, so permitting controlled retention with a high safety profile.

Thus according to one aspect of the present

09673150 121100



invention there is provided an ultrasound contrast agent comprising an injectable oil-in-water emulsion wherein there are gas-containing nucleation sites associated with droplets of the dispersed oil phase.

5       The invention further provides a method of generating enhanced images of a human or non-human animal subject which comprises the steps of injecting a contrast agent as defined above into the vascular system of said subject and generating an ultrasound image of at  
10       least a part of said subject.

      The dispersed oil phase may comprise one or more appropriately volatile components where at least one component is at least partially insoluble in and immiscible with water. This component or mixture of  
15       components is advantageously a liquid at processing and storage temperature, which may for example be as low as -10°C if the aqueous phase contains appropriate antifreeze material, while being a gas or exhibiting sufficient vapour pressure, e.g. at least 50 mm Hg,  
20       preferably at least 100 mm Hg, at body temperature. Other less volatile substantially water-insoluble and water-immiscible components may if desired also be present in the oil phase.

      Appropriate volatile components may, for example,  
25       be selected from the various lists of emulsifiable low boiling liquids given in the aforementioned WO-A-9416739, the contents of which are incorporated herein by reference. Specific examples of emulsifiable oil phase components include aliphatic ethers such as  
30       diethyl ether; polycyclic oils or alcohols such as menthol, camphor or eucalyptol; heterocyclic compounds such as furan or dioxane; aliphatic hydrocarbons, which may be saturated or unsaturated and straight chained or branched, e.g. as in n-butane, n-pentane, 2-  
35       methylpropane, 2-methylbutane, 2,2-dimethylpropane, 2,2-dimethylbutane, 2,3-dimethylbutane, 1-butene, 2-butene, 2-methylpropene, 1,2-butadiene, 1,3-butadiene, 2-methyl-

09673160 134100

1-butene, 2-methyl-2-butene, isoprene, 1-pentene, 1,3-pentadiene, 1,4-pentadiene, butenyne, 1-butyne, 2-butyne or 1,3-butadiyne; cycloaliphatic hydrocarbons such as cyclobutane, cyclobutene, methylcyclopropane or cyclopentane; and halogenated low molecular weight hydrocarbons (e.g. containing up to 7 carbon atoms). Representative halogenated hydrocarbons include dichloromethane, methyl bromide, 1,2-dichloroethylene, 1,1-dichloroethane, 1-bromoethylene, 1-chloroethylene, ethyl bromide, ethyl chloride, 1-chloropropene, 3-chloropropene, 1-chloropropane, 2-chloropropane and t-butyl chloride. Advantageously at least some of the halogen atoms are fluorine atoms, for example as in dichlorofluoromethane, trichlorofluoromethane, 1,2-dichloro-1,2-difluoroethane, 1,2-dichloro-1,1,2,2-tetrafluoroethane, 1,1,2-trichloro-1,2,2-trifluoroethane, 2-bromo-2-chloro-1,1,1-trifluoroethane, 2-chloro-1,1,2-trifluoroethyl difluoromethyl ether, 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether, partially fluorinated alkanes (e.g. pentafluoropropanes such as 1H,1H,3H-pentafluoropropane, hexafluorobutanes, nonafluorobutanes such as 2H-nonafluoro-t-butane, and decafluoropentanes such as 2H,3H-decafluoropentane), partially fluorinated alkenes (e.g. heptafluoropentenes such as 1H,1H,2H-heptafluoropent-1-ene, and nonafluorohexenes such as 1H,1H,2H-nonafluorohex-1-ene), fluorinated ethers (e.g. 2,2,3,3,3-pentafluoropropyl methyl ether or 2,2,3,3,3-pentafluoropropyl difluoromethyl ether) and, more preferably, perfluorocarbons. Examples of perfluorocarbons include perfluoroalkanes such as perfluorobutanes, perfluoropentanes, perfluorohexanes (e.g. perfluoro-2-methylpentane), perfluoroheptanes, perfluorooctanes, perfluorononanes and perfluorodecanes; perfluorocycloalkanes such as perfluorocyclobutane, perfluorodimethyl-cyclobutanes, perfluorocyclopentane and perfluoromethylcyclopentane; perfluoroalkenes such

as perfluorobutenes (e.g. perfluorobut-2-ene or perfluorobuta-1,3-diene), perfluoropentenenes (e.g. perfluoropent-1-ene) and perfluorohexenes (e.g. perfluoro-2-methylpent-2-ene or perfluoro-4-methylpent-2-ene); perfluorocycloalkenes such as perfluorocyclopentene or perfluorocyclopentadiene; and perfluorinated alcohols such as perfluoro-t-butanol.

Such at least partially water-insoluble/immiscible volatile substances may contain dissolved materials which significantly increase the vapour pressure of the mixture. Such solute materials include gases such as air; nitrogen; oxygen; carbon dioxide; hydrogen; inert gases such as helium, argon, xenon or krypton; sulphur fluorides such as sulphur hexafluoride, disulphur decafluoride or trifluoromethylsulphur pentafluoride; selenium hexafluoride; optionally halogenated silanes such as methylsilane or dimethylsilane; low molecular weight hydrocarbons (e.g. containing up to 7 carbon atoms), for example alkanes such as methane, ethane, a propane, a butane or a pentane, cycloalkanes such as cyclopropane, cyclobutane or cyclopentane, alkenes such as ethylene, propene, propadiene or a butene, or alkynes such as acetylene or propyne; ethers such as dimethyl ether; ketones; esters; halogenated low molecular weight hydrocarbons (e.g. containing up to 7 carbon atoms); or mixtures of any of the foregoing. Gases such as air, oxygen and carbon dioxide, which have substantial solubility in fluorocarbon liquids, are preferred.

The emulsion will typically be stabilized by one or more surfactants or other encapsulating material. It will be appreciated that the nature of such material may significantly affect factors such as the rate of growth of volatilised gas. In general a wide range of surfactants may be useful, for example selected from the extensive lists given in EP-A-0727225, the contents of which are incorporated herein by reference. Representative examples of useful surfactants include

5 fatty acids (e.g. straight chain saturated or  
unsaturated fatty acids, for example containing 10-20  
carbon atoms) and carbohydrate and triglyceride esters  
thereof, phospholipids (e.g. a lecithin or a fluorine-  
10 containing phospholipid), proteins (e.g. albumins such  
as human serum albumin), block copolymer surfactants  
(e.g. polyoxyethylene-polyoxypropylene block copolymers  
such as Pluronic, or extended polymers such as  
acyloxyacyl polyethylene glycols, for example  
15 polyethyleneglycol methyl ether 16-hexadecanoyloxy-  
hexadecanoate, e.g. wherein the polyethylene glycol  
moiety has a molecular weight of 2300, 5000 or 10000),  
fluorine-containing surfactants (e.g. as marketed under  
the trade names Zonyl and Fluorad, or as described in  
20 WO-A-9639197, the contents of which are incorporated  
herein by reference), and cationic surfactants, for  
example comprising one or more quaternary ammonium  
groups and one or more lipid groups such as long chain  
(e.g. C<sub>10-30</sub>) alkyl or alkanoyl groups.

25 The emulsion droplets may also be stabilised by  
wall-forming encapsulating material, so that the  
dispersed phase is in the form of microcapsules  
containing the volatile liquid, or by incorporation into  
porous structures such as latex particles.  
25 Representative wall-forming materials include polymers  
such as polylactic acid, polycaprolactone,  
polycyanoacrylate and polyesters (e.g. as described in  
WO-A-9317718).

30 Nucleation sites may be present within the  
dispersed oil phase droplets or within surfactant or  
other encapsulating or stabilizing membranes surrounding  
the droplets; such membranes may themselves act as  
nucleation sites *per se*. Alternatively appropriate  
nucleation sites may be present in contact with the  
35 outside of such membranes.

Where the nucleation sites are present within the  
oil droplets they may, for example, take the form of

09673160 121100

dispersed gas microbubbles, e.g. in the form of free microbubbles, surfactant- or lipid-stabilised microbubbles, polymer- or protein-encapsulated microbubbles, gas-containing porous solid microparticles such as aerogels or zeolites, gas entrapped in holes crevices or other irregularities of rough-surfaced solid microparticles, gas-containing polymeric microparticles or gas-containing entities such as fullerenes, clathrates or nanotubes. Such contrast agents may readily be prepared by dispersing the nucleation site-containing material in the oil phase and then generating an oil-in-water emulsion in *per se* known manner, using one or more appropriate dispersing agents.

In order to facilitate dispersion, the interfacial properties of nucleation sites may, for example, be varied by selection of a dispersing agent for the nucleation sites, or by chemical modification of the nucleation site surface, e.g. by silanisation or plasma modification. The presence of surface irregularities, cavities, edges, crevices or other structural defects which assist a gas phase in spreading on the interface may also be advantageous.

If desired, the nucleation sites may be selected to have interfacial properties which allow them to be located at the water-volatile oil interface. This may, for example, be achieved by choosing a dispersing agent for the nucleation sites which allows the surface of a nucleation site to be partly wetted by both the volatile oil and the aqueous phase. If necessary the surface of the nucleation site may be adjusted by chemical modification (e.g. plasma modification), rinsing etc.

In embodiments of the invention where it is desired that microbubble generation should occur spontaneously *in vivo*, it is generally preferred that the boiling point of the dispersed oil phase of the emulsion should not exceed 42°C, i.e. that the sum of partial pressures from the volatile component(s) of the oil phase should

09673460-12400

- 10 -

exceed one atmosphere at 42°C.

In other embodiments of the invention microbubbles may be generated either *in vivo* or immediately prior to injection by appropriate temperature and/or pressure modifications or application of external activating influences such as sound, ultrasound or radiation. When external activating influences are applied, emulsions in which the oil phase has a higher boiling point, e.g. up to 60°C, may also be useful, since the external activation may cause sufficient evaporation of the oil phase *in vivo* despite its boiling point being more removed from body temperature.

Microbubbles generated from contrast agents according to the present invention are characterised by a readily controllable rate of growth and final size; they may, for example be designed to grow to a size of e.g. 10-20  $\mu\text{m}$  in order to exhibit controlled retention in tissue microvasculature, e.g. in the myocardium, or may be designed to grow to a size of e.g. 1-7  $\mu\text{m}$  so that they behave as free-flowing contrast agents.

It will be appreciated that liquid-to-gas phase shift in emulsion droplets in the presence of nucleation sites ensures a highly efficient and rapid transformation of the liquid, hence limiting diffusion of volatile substance between separated particles and thus limiting uncontrolled bubble growth. In this respect, the material inside one emulsion droplet may be transformed to one bubble. Assuming a gas which can be described by the ideal gas law [Equation (1)],

$$pV = nRT \quad (1)$$

where  $n$  is number of moles of substance to make one bubble and is related to the radius of the emulsion droplet,  $r_e$ , by Equation (2)

- 11 -

$$n = \frac{d \cdot V_e}{M_w} = \frac{d}{M_w} \cdot \frac{4}{3} \pi r_e^3 \quad (2)$$

where  $d$  is the density of the liquid phase,  $M_w$  is the molecular weight of the volatile substance and  $V_e$  is the volume of the liquid droplet, then inserting Equation (2) into the ideal gas law Equation (1), and expressing  
 5 the volume  $V$  of the obtained gas bubble by its radius  $r_b$  gives;

$$r_b = r_e \sqrt[3]{\frac{R T d}{p M_w}} \approx 0.29 \cdot r_e \sqrt[3]{\frac{d}{M_w}} \quad (3)$$

For a typical volatile solvent, for example perfluoropentane,  $d$  is 1.66 g/ml,  $M_w = 288$  g/mol and using  $T = 298$  K and  $p = 1$  atm, gives  $r_b \approx 5.2 r_e$ . The  
 10 emulsion droplet should therefore have a size slightly below  $2 \mu\text{m}$  in order to give a microbubble of size  $10 \mu\text{m}$  which is therefore capable of temporary retention.

For the nucleation site to occupy 50% of such an emulsion droplet, its size should be below  $1.6 \mu\text{m}$ . More  
 15 preferably the nucleation site should occupy less than 20% of the emulsion droplet, so that its size should be below  $1.2 \mu\text{m}$ ; even more preferably, the nucleation site should occupy less than 10% of the liquid volume and so should have a size below  $1 \mu\text{m}$ .

20 In order to ensure boiling of a sufficiently high number of emulsion droplets, a sufficiently high number of nucleation sites should be added. The nucleation sites will be distributed on the liquid carrier particles by simple Boltzmann distribution, and  
 25 calculations may be made to estimate the amount of nucleation sites to be added for a given fraction of the liquid carrier particles to contain at least one nucleation site.

05673160 12400

- 12 -

Activation of the phase transition from liquid to gas may be obtained by simply heating to temperatures above the boiling point of the volatile liquid. In order for phase transition to be activated on injection by  
5 utilizing the increase in temperature to body temperature, a volatile oil with boiling point below body temperature should be used. However, since bubble nucleation rate may be low also at elevated temperatures, the volatile liquid may have a boiling  
10 point well below body temperature. In such a superheated dispersion, presence of nucleation sites may lower the barrier for phase shift so that nucleation can be induced by means of an external influence.

Products in which gas formation is activated by  
15 ultrasonication or like treatment may be particularly advantageous in that they may be highly storage-stable prior to activation and use.

It will be appreciated that the dispersed gas content of contrast agents according to the invention  
20 will tend to be temporarily retained in tissue in concentrations proportional to the regional rate of tissue perfusion. Accordingly, when using ultrasound imaging modalities such as conventional or harmonic B-mode imaging where the display is derived directly from  
25 return signal intensities, images of such tissue may be interpreted as perfusion maps in which the displayed signal intensity is a function of local perfusion. This is in contrast to images obtained using free-flowing contrast agents, where the regional concentration of  
30 contrast agent and corresponding return signal intensity depend on the actual blood content rather than the rate of perfusion of local tissue.

In cardiac studies, where perfusion maps are derived from return signal intensities in accordance  
35 with this embodiment of the invention, it may be advantageous to subject a patient to physical or pharmacological stress in order to enhance the

09073160 121100



- 13 -

distinction, and thus the difference in image intensities, between normally perfused myocardium and any myocardial regions supplied by stenotic arteries. As is known from radionuclide cardiac imaging, such stress induces vasodilatation and increased blood flow in healthy myocardial tissue, whereas blood flow in underperfused tissue supplied by a stenotic artery is substantially unchanged since the capacity for arteriolar vasodilatation is already exhausted by inherent autoregulation seeking to increase the restricted blood flow.

The application of stress as physical exercise or pharmacologically by administration of adrenergic agonists may cause discomfort such as chest pains in patient groups potentially suffering from heart disease, and it is therefore preferable to enhance the perfusion of healthy tissue by administration of a vasodilating drug, for example selected from adenosine, dipyridamole, nitroglycerine, isosorbide mononitrate, prazosin, doxazosin, dihydralazine, hydralazine, sodium nitroprusside, pentoxifylline, amlodipine, felodipine, isradipine, nifedipine, nimodipine, verapamil, diltiazem and nitrous oxide. In the case of adenosine this may lead to in excess of fourfold increases in coronary blood flow in healthy myocardial tissue, greatly increasing the uptake and temporary retention of contrast agents in accordance with the invention and thus significantly increasing the difference in return signal intensities between normal and hypoperfused myocardial tissue. Because an essentially physical entrapment process is involved, retention of contrast agents according to the invention is highly efficient; this may be compared to the uptake of radionuclide tracers such as thallium 201 and technetium sestamibi, which is limited by low contact time between tracer and tissue and so may require maintenance of vasodilatation for the whole period of blood pool distribution for the

09673160 421100

tracer (e.g. 4-6 minutes for thallium scintigraphy) to ensure optimum effect. The contrast agents of the invention, on the other hand, do not suffer such diffusion or transport limitations, and since their retention in myocardial tissue may also rapidly be terminated by the methods described above, the period of vasodilatation needed to achieve cardiac perfusion imaging in accordance with this embodiment of the invention may be very short, for example less than one minute. This will reduce the duration of any possible discomfort caused to patients by administration of vasodilator drugs.

In view of the fact that the required vasodilatation need only be short lasting, adenosine is a particularly useful vasodilating drug, being both an endogenous substance and having a very short-lasting action as evidenced by a blood pool half-life of only a few seconds. Vasodilatation will accordingly be most intense in the heart, since the drug will tend to reach more distal tissues in less than pharmacologically active concentrations. It will be appreciated that because of this short half-life, repeated injection or infusion of adenosine may be necessary during cardiac imaging in accordance with this embodiment of the invention; by way of example, an initial administration of 150  $\mu\text{g/kg}$  of adenosine may be made substantially simultaneously with administration of the contrast agent composition, followed 10 seconds later by slow injection of a further 150  $\mu\text{g/kg}$  of adenosine, e.g. over a period of 20 seconds.

The contrast agents of the invention may usefully be employed in therapeutic applications such as drug delivery agents. Thus hydrophobic drugs may be dissolved in the volatile oil phase to achieve an advantageously high drug load. Therapeutics may also be incorporated into any encapsulating membrane or may be dissolved in the aqueous carrier phase. Therapeutics

Without being bound with theoretical considerations, it is believed that evaporation of the volatile oil droplets will accelerate release of a dissolved therapeutic drug due to the increased concentration of drug in the liquid droplet, which may easily exceed the solubility level. Drug uptake may be also enhanced due to local shear and effects from "microstreaming" induced from the microbubble formation.

The following non-limitative Examples serve to illustrate the invention.

Example 1

A spatula edge of micronised kaolin is added to 2 ml perfluoropentane (b.p. 28°C) containing 0.2 ml Fluorad™ FC-171 surfactant. A milky white dispersion is obtained after gently shaking by hand. 0.1 ml of the above dispersion is mixed with 1 ml water by shaking on an Espe Capmix® for 30 seconds, yielding an emulsion with droplet size slightly above 1 µm.

A droplet of the emulsion is placed on a cooling/heating stage, and heated to 37°C while following the process in a microscope. Several 10 µm droplets appear, demonstrating a rapid liquid-to-gas phase shift in the emulsion droplets.

A tube containing the emulsion is dipped in a water bath maintained at 37°C so that only one part of the emulsion is heated. The turbidity immediately increases significantly in that part of the emulsion which is heated relatively to the non-heated emulsion, demonstrating the formation of small gas bubbles after heating.

Example 2

A spatula edge of micronised zeolite is added to 2 ml perfluoropentane (b.p. 28°C) containing 0.2 mg perfluorooctanoic acid. The sample is sonicated using a Branson W385 sonicator horn at 50% output power for two minutes while keeping the sample in an ice bath. 0.1 ml of the above dispersion is mixed with 1 ml water by shaking on an Espe Capmix® for 45 seconds, yielding an emulsion.

A sample of the emulsion (1 µl) is suspended in Isoton II (55 ml) at room temperature, and acoustic attenuation

- 17 -

is measured as a function of time using two broadband transducers with centre frequencies of 3.5 MHz and 5.0 MHz respectively, in a pulse-echo technique. The acoustic attenuation is weak. The sample is then heated step-wise and acoustic attenuation is measured for each temperature. When the sample temperature is around 30°C, a substantial increase in acoustic attenuation can be observed. This experiment demonstrates how a nucleation site-containing emulsion of a volatile substance can transform to a microbubble dispersion around its boiling point. It also demonstrates the change in acoustic properties and the product's usefulness as an ultrasound contrast agent.

15 Example 3 (comparative)

Example 2 is repeated without adding micronised zeolite to the perfluoropentane phase. When characterising the emulsion using the acoustic attenuation measurement technique, heating to temperatures well above 40°C leads only to a slight increase in acoustic attenuation. This demonstrates the requirement for nucleation sites to be associated with the dispersed phase.

25 Example 4

a) 5 ml of a 5% w/v solution of the polymer from Example 2(a) of WO-A-9607434 in (-)-camphene, maintained at 60°C, is added to 15 ml of a 5% w/v solution of human serum albumin in water at the same temperature. The mixture is mixed hot with an Ultra Turax T25 mixer at 20,000 rpm for 1 minute. Thereafter, the emulsion is homogenised at 60°C using an Emulsiflex C5 high-pressure homogeniser, operating at a peak pressure of 200,000 kPa and allowing five passes of the sample. The median size of the obtained emulsion is around 300 nm. The emulsion is then frozen on a dry ice/methanol bath and

- 18 -

lyophilised for 48 hours, giving a white powder. Electron microscopy indicates the formation of gas-filled nanocapsules. The polymer particles are dispersed in water and excess human serum albumin is removed by dialysis. The remaining polymer nanocapsules are dried under reduced pressure.

b) A spatula edge of the washed, hollow polymer-stabilised nanocapsules from (a) above is added to 2 ml perfluorodimethylcyclobutane (b.p. 45°C) containing 0.2 ml perfluorooctanoic acid. The sample is shaken on a laboratory shaker for one hour, yielding a dispersion of gas-filled nanocapsules dispersed in perfluorodimethylcyclobutane. 0.1 ml of the above dispersion is mixed with 1 ml water by shaking on an Espe Capmix® for 45 seconds, yielding an emulsion.

c) A droplet of the emulsion from (b) above is placed on a cooling/heating stage and heated to 50°C, while following the process in a microscope. Several 10 µm droplets appear when the temperature passes 45°C, demonstrating a rapid liquid-to-gas phase shift in the emulsion droplets.

d) A tube containing diluted emulsion from (b) above is dipped in a water bath maintained at 50°C, so that only part of the emulsion is heated. The turbidity immediately increases significantly in the heated part of the emulsion relative to the non-heated part, demonstrating the formation of small gas bubbles on heating.

e) A sample of the emulsion from (b) above (1 µl) is suspended in Isoton II (55 ml) at room temperature, and acoustic attenuation is measured as a function of time using two broadband transducers with centre frequencies of 3.5 MHz and 5.0 MHz respectively, in a pulse-echo

001160 121100

technique. The acoustic attenuation is weak. The sample is then heated step-wise and acoustic attenuation is measured for each temperature. When the sample temperature passes 35-40°C, a substantial increase in acoustic attenuation can be observed. This experiment demonstrates how a nucleation site-containing emulsion of a volatile substance can transform to a microbubble dispersion well below its boiling point when the emulsion is exposed to external ultrasound. It also demonstrates the change in acoustic properties and the product's usefulness as an ultrasound contrast agent.

#### Example 5

A dog is anaesthetised, a mid-line sternotomy is performed, and the anterior pericardium is removed. Mid-line short-axis B-mode imaging of the heart is performed through a low-attenuating 30 mm silicone rubber spacer, using an ATL HDI-3000 scanner equipped with a P3-2 transducer. The framerate is 40 Hz and the mechanical index is 1.1. An amount of the polymer nanocapsule-containing perfluorodimethylcyclobutane emulsion of Example 4(b), corresponding to 0.2 µl perfluorodimethylcyclobutane/kg body weight, is injected intravenously into the dog. A substantial rise in echo intensity from the myocardium is seen, starting some 20 seconds after the injection and lasting for 20 minutes. The increase in myocardial opacification is seen at a time when the ventricles are almost emptied of contrast. The observed efficacy is therefore due to microbubbles retarded in the myocardium.

#### Example 6 (comparative)

Example 5 is repeated except that a perfluorodimethylcyclobutane emulsion phase is used without added polymeric nanocapsules. In vivo ultrasound imaging

- 20 -

indicates limited acoustic efficacy of the emulsion.  
This comparative experiment shows the necessity for gas-filled nucleation site associated with the emulsion droplets.

09673450-121100



09/673160

529 Rec'd PCT/PTC 10 OCT 2000

Claims

1. An ultrasound contrast agent comprising an injectable oil-in-water emulsion wherein there are  
5 heterogeneous gas-containing nucleation sites associated with droplets of the dispersed oil phase.
2. A contrast agent as claimed in claim 1 wherein the nucleation sites are present within dispersed oil phase  
10 droplets.
3. A contrast agent as claimed in claim 2 wherein the nucleation sites comprise free gas microbubbles, surfactant- or lipid-stabilised gas microbubbles,  
15 polymer- or protein-encapsulated gas microbubbles, gas-containing porous solid microparticles, gas-containing rough-surfaced solid microparticles, gas-containing polymeric microparticles, or gas-containing fullerenes, clathrates or nanotubes.  
20
4. A contrast agent as claimed in claim 1 wherein nucleation sites are present within membranes stabilising the dispersed oil phase droplets or in contact with the outside of such membranes.  
25
5. A contrast agent as claimed in any of the preceding claims wherein the oil phase comprises one or more components selected from aliphatic ethers, polycyclic oils and alcohols, heterocyclic compounds, aliphatic  
30 hydrocarbons, cycloaliphatic hydrocarbons and halogenated hydrocarbons, said component(s) having a boiling point not exceeding 60°C.
6. A contrast agent as claimed in claim 5 wherein the  
35 oil phase comprises one or more perfluorocarbons.

- 22 -

7. A contrast agent as claimed in claim 6 wherein said perfluorocarbon is selected from perfluorobutanes, perfluoropentanes, perfluorohexanes, perfluorocyclobutane, perfluorodimethylcyclobutanes, perfluorocyclopentane, perfluoromethylcyclopentane, perfluorobutenes, perfluorobutadienes, perfluoropentenes, perfluorohexenes, perfluorocyclopentene, perfluorocyclopentadiene and perfluoro-t-butanol.
8. A contrast agent as claimed in any of the preceding claims wherein the oil phase contains a gaseous solute.
9. A contrast agent as claimed in claim 8 wherein the oil phase comprises air, oxygen or carbon dioxide dissolved in a liquid fluorocarbon.
10. A contrast agent as claimed in any of the preceding claims wherein the dispersed oil phase droplets are stabilised by a surfactant selected from fatty acids, carbohydrate and triglyceride esters of fatty acids, phospholipids, proteins, block copolymer surfactants, fluorine-containing surfactants and cationic surfactants.
11. A contrast agent as claimed in any of claims 1 to 9 wherein the dispersed oil phase droplets are stabilised by polymeric wall-forming encapsulating material or by incorporation into porous latex particles.
12. A contrast agent as claimed in any of the preceding claims wherein the oil phase has a boiling point not exceeding 42°C.
13. A combined preparation for simultaneous, separate or sequential use as a contrast agent in ultrasound imaging, said preparation comprising:

- 23 -

- i) a contrast agent as claimed in any of the preceding claims, and
- ii) a vasodilator drug.

5 14. A combined preparation as claimed in claim 13 wherein said vasodilator drug is adenosine.

10 15. A drug delivery agent comprising a contrast agent as claimed in any of claims 1 to 12 together with a therapeutic drug.

15 16. A drug delivery agent as claimed in claim 15 wherein a hydrophobic drug is dissolved in the oil phase.

17. A drug delivery agent as claimed in claim 15 wherein the drug is present as nano- or micro-sized particles.

20 18. A method of generating enhanced images of a human or non-human animal subject which comprises the steps of injecting a contrast agent as claimed in any of claims 1 to 14 into the vascular system of said subject and generating an ultrasound image of at least a part of  
25 said subject.

19. A method as claimed in claim 18 wherein microbubble growth from the contrast agent is activated within the subject by application of external activation.

30 20. A method as claimed in claim 19 wherein said external activation comprises ultrasound irradiation.

21. Use of a contrast agent as claimed in any of claims  
35 1 to 12 in ultrasound therapy.

00673160.124100

- 24 -

22. Use as claimed in claim 21 wherein said therapy involves cell killing or blocking of blood flow to a site of interest.

09673460.424.400



Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**DECLARATION FOR UTILITY OR  
DESIGN  
PATENT APPLICATION  
(37 CFR 1.63)**

☐ Declaration Submitted with Initial Filing OR ☒ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number NIDN-10369

First Named Inventor Balinov

**COMPLETE IF KNOWN**

Application Number 09 / 673,160

Filing Date 11-Oct-2000

Group Art Unit To be assigned

Examiner Name To be assigned

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Ultrasound Contrast Agent

the specification of which (Title of the Invention)

☐ is attached hereto  
OR

☒ was filed on (MM/DD/YYYY) 10/11/2000 as United States Application Number or PCT International

Application Number 09/673,160 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
9808581.4	GB	04/22/1998	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.
60/084,882	05/08/1998	

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)  
Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/GB99/01234 which is a CIP of US 60/084,882 filed 05/08/1998	04/22/1999	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business with the Patent and Trademark Office connected therewith: ☒ Customer Number 22840

OR ☐ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☒ Customer Number 22840 OR ☐ Correspondence address below

Name					
Address					
Address					
City		State		ZIP	
Country		Telephone		Fax	


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any)) Balin Family Name or Surname Balinov

Inventor's Signature	<i>Balinov</i>			Date	11/11-00
Residence: City	Oslo	State		Country	Norway
Post Office Address	Grefsenkollv. 12A leil. 327				
Post Office Address					
City	Oslo	State		ZIP	N-0490
				Country	Norway

☒ Additional inventors are being named on the 1 supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto



Please type a plus sign (+) inside this box → ☐

PTO/SB/02A (3-97)  
Approved for use through 9/30/98. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION

ADDITIONAL INVENTOR(S)  
Supplemental Sheet  
Page 1 of 1

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle [if any])		Family Name or Surname				
Road		Skurtveit				
Inventor's Signature	Road Skurtveit			Date	10/11-00	
Residence: City	Nittedal	State	Country	Norway	Citizenship	NO
Post Office Address		Nordfaret 1A				
Post Office Address						
City	Nittedal	State	ZIP	N-1484	Country	Norway
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle [if any])		Family Name or Surname				
Unni		Nordby Wiggen				
Inventor's Signature	U. N. Wiggen			Date	15/11-00	
Residence: City	Rasta	State	Country	Norway	Citizenship	NO
Post Office Address		Vestaveien 11				
Post Office Address						
City	Rasta	State	ZIP	N-1476	Country	Norway
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor				
Given Name (first and middle [if any])		Family Name or Surname				
Jonny		Ostensen				
Inventor's Signature	Jonny Ostensen			Date	10/11-00	
Residence: City	Oslo	State	Country	Norway	Citizenship	NO
Post Office Address		Lonneveien 8C				
Post Office Address						
City	Oslo	State	ZIP	N-1053	Country	Norway

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.